Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $326,270 | $84,524 | $39,571 | $100,868 |
| - Cash | $8,740 | $12,620 | $13,159 | $63,458 |
| + Debt | $1,122 | $1,374 | $2,601 | $3,647 |
| Enterprise Value | $318,652 | $73,278 | $29,013 | $41,057 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$27,463 | -$23,256 | -$32,198 | -$38,170 |
| % Margin | – | – | – | – |
| Net Income | -$62,293 | -$27,029 | -$41,307 | -$43,241 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.02 | -0.563 | -0.89 | -1.03 |
| % Growth | -81.2% | 36.8% | 13.6% | – |
| Operating Cash Flow | -$25,424 | -$23,935 | -$27,023 | -$36,715 |
| Capital Expenditures | $0 | -$34 | -$269 | -$5 |
| Free Cash Flow | -$25,424 | -$23,969 | -$27,292 | -$36,720 |